EcoDrugPlus

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled

Ensembl ID : ENSXETG00000024787
Gene Symbol: HTR2C
8 Enzyme and pathways 5 View Cross-references
226 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine (Serotonin) Receptor 3a, Ionotropic

Ensembl ID : ENSXETG00000031115
Gene Symbol: HTR3A
3 Enzyme and pathways 4 View Cross-references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine (Serotonin) Receptor 3b, Ionotropic

Ensembl ID : ENSXETG00000031022
Gene Symbol: HTR3B
3 Enzyme and pathways 5 View Cross-references
174 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine (Serotonin) Receptor 4, G Protein-Coupled

Ensembl ID : ENSXETG00000019373
Gene Symbol: HTR4
8 Enzyme and pathways 5 View Cross-references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine (Serotonin) Receptor 5a, G Protein-Coupled

Ensembl ID : ENSXETG00000036447
Gene Symbol: HTR5A
8 Enzyme and pathways 5 View Cross-references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine (Serotonin) Receptor 7, Adenylate Cyclase-Coupled

Ensembl ID : ENSXETG00000031961
Gene Symbol: HTR7
10 Enzyme and pathways 5 View Cross-references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSXETG00000043649
Gene Symbol: ARAF
7 Enzyme and pathways 5 View Cross-references
191 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSXETG00000001464
Gene Symbol: ABL1
28 Enzyme and pathways 5 View Cross-references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adam Metallopeptidase Domain 17

Ensembl ID : ENSXETG00000008262
Gene Symbol: ADAM17
5 Enzyme and pathways 5 View Cross-references
282 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSXETG00000013638
Gene Symbol: ADAMTS5
6 Enzyme and pathways 5 View Cross-references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSXETG00000031142
Gene Symbol: ALK
3 Enzyme and pathways 4 View Cross-references
194 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Apex Nuclease (Multifunctional Dna Repair Enzyme) 1

Ensembl ID : ENSXETG00000024773
Gene Symbol: APEX1
5 View Cross-references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).